Intermittent Explosive Disorder disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INT025 MIFTS: 38	Intermittent Explosive Disorder malady Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Intermittent Explosive Disorder

Aliases & Descriptions for Intermittent Explosive Disorder:

Name: Intermittent Explosive Disorder ¹² ¹⁴ ⁶⁹

Explosive Personality Disorder ¹² ⁶⁹

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Mental and behavioural disorders

Disorders of adult personality and behaviour

Specific personality disorders

Emotionally unstable personality disorder

External Ids:

Disease Ontology ¹² DOID:12401

ICD10 ³³ F60.3 F63.81

ICD9CM ³⁵ 301.3 312.34

MeSH ⁴² D007174

NCIt ⁴⁷ C94332

SNOMED-CT ⁶⁴ 191759005 192096007 192488005 more

UMLS ⁶⁹ C0021776 C0152183

Sources

Summaries for Intermittent Explosive Disorder

Disease Ontology : ¹² An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness.

MalaCards based summary : Intermittent Explosive Disorder, also known as explosive personality disorder, is related to pyromania and coloboma of iris. An important gene associated with Intermittent Explosive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Monoamine GPCRs. The drugs Guanfacine and Naratriptan have been mentioned in the context of this disorder. Affiliated tissues include amygdala and brain, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia : ⁷¹ Intermittent explosive disorder (sometimes abbreviated as IED) is a behavioral disorder characterized by... more...

Sources

Related Diseases for Intermittent Explosive Disorder

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)

id	Related Disease	Score	Top Affiliating Genes
1	pyromania	11.0
2	coloboma of iris	10.2	CRP IL6
3	apperceptive agnosia	10.2	CRP HTR1A SLC6A4
4	tactile agnosia	10.2	SMOC1 SMUG1
5	dry eye syndrome	10.2	HTR1A HTR7 SLC6A4
6	renpenning syndrome	10.2	HTR1A HTR7 SLC6A4
7	cutaneous sclerosis	10.2	CRP IL6
8	antisocial personality disorder	10.2	HTR1A SMOC1
9	tinea pedis	10.1	HTR1A HTR7 SLC6A4
10	human immunodeficiency virus infectious disease	10.1	CRP IL6 SMUG1
11	keratosis	10.1	HTR1A HTR7 SLC6A4
12	lichen disease	10.1	HTR1A IL6 SLC6A4
13	toxic myocarditis	10.1	ADRB1 CRP IL6
14	fallopian tube adenomatoid tumor	10.1	CRP SMUG1
15	abnormal pupillary function	10.1	HTR1A HTR7
16	stiff-person syndrome	10.1	CRP IL6 SMUG1
17	shoulder impingement syndrome	10.1	CRP IL6
18	chronic eosinophilic pneumonia	10.1	HTR1A PRL SLC6A4
19	ellis-van creveld syndrome	10.1	CHRFAM7A CHRNA7 HTR1A SLC6A4
20	unilateral multicystic dysplastic kidney	10.1	CRP IL6
21	nodular nonsuppurative panniculitis	10.1	CRP IL6 SMOC1
22	personality disorder	10.0
23	conjunctival pigmentation	10.0	HTR7 SLC6A4
24	adrenal adenoma	10.0	CRP IL6 NPY
25	benign epilepsy with centrotemporal spikes	10.0	HTR1A IL6 NPY SLC6A4
26	chronic conjunctivitis	10.0	CHRNA7 HTR1A PRL SLC6A4
27	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy	10.0	NPY PRL SLC6A4
28	alzheimer disease 17	10.0	HTR1A HTR7 PRL SLC6A4
29	hepatitis d	10.0	HTR1A NPY PRL SLC6A4
30	microcephaly 13, primary, autosomal recessive	9.9	GOLPH3 HTR1A HTR7 SLC6A4
31	body dysmorphic disorder	9.9	CRP IL6 NPY PRL
32	breast hemangiopericytoma	9.9	CRP IL6 PRL SMOC1
33	mucinous adenocarcinoma	9.9	GABRA2 NPY PRL SLC6A4
34	autism spectrum disorder	9.9	HTR7 MFAP4 SLC6A4
35	preeclampsia/eclampsia 5	9.8	GABRA2 HTR1A HTR7 NPY SLC6A4
36	obsessive-compulsive disorder	9.8
37	prader-willi syndrome	9.8
38	bipolar disorder	9.8
39	borderline personality disorder	9.8
40	obsessive-compulsive personality disorder	9.8
41	avoidant personality disorder	9.8
42	schizophrenia	9.5	CHRFAM7A CHRNA7 CRP HTR1A HTR7 NPY
43	luxation of globe	7.9	ADRB1 CGA CHRFAM7A CHRNA7 CRP CTSH

Comorbidity relations with Intermittent Explosive Disorder via Phenotypic Disease Network (PDN):

Acute Cystitis	Alzheimer Disease
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:

Sources

Symptoms & Phenotypes for Intermittent Explosive Disorder

MGI Mouse Phenotypes related to Intermittent Explosive Disorder:

⁴⁴

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	9.73	HTR7 IL6 NPY PRL SLC6A4 SMUG1
2	nervous system	MP:0003631	9.32	CGA CHRNA7 GABRA2 HTR1A HTR7 IL6

Sources

Drugs & Therapeutics for Intermittent Explosive Disorder

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Guanfacine

Approved, Investigational

Phase 4

29110-47-2

3519

Synonyms:

29110-47-2

29110-48-3 (mono-hydrochloride)

AC1L1G4B

BPBio1_000415

BRD-K32830106-003-03-0

BSPBio_000377

C07037

C9H9Cl2N3O

CAS-29110-48-3

CHEMBL862

CID3519

D08031

DB01018

EINECS 249-442-8

Estulic

Estulic (TN)

G1043_SIGMA

Guanfacina

Guanfacina [INN-Spanish]

GUANFACINE

Guanfacine (INN)

Guanfacine [INN:BAN]

Guanfacine Monohydrochloride

Guanfacinum

Guanfacinum [INN-Latin]

Intuniv

L000286

L013430

Lon798

Lopac0_000519

Lopac-G-1043

LS-174236

MolPort-003-941-447

N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide

N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide

NCGC00015469-01

NCGC00015469-02

NCGC00015469-06

NCGC00024950-01

NCGC00024950-02

NCGC00024950-03

Prestwick0_000339

Prestwick1_000339

Prestwick2_000339

Prestwick3_000339

SPBio_002298

SPD 503

Tocris-1030

UNII-30OMY4G3MK

ZINC03872738

Naratriptan

Approved, Investigational

Phase 4

143388-64-1, 121679-13-8

4440

Synonyms:

121679-13-8

AC1L1I6A

AC-5013

Amerge, Naramig,Naratriptan

BIDD:GT0312

C07792

CHEBI:7478

CHEMBL1278

CID4440

Colatan

D08255

DB00952

InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H

L000432

LS-83062

MolPort-005-932-823

Naramig

Naramig (TN)

naratriptan

Naratriptan (INN)

naratriptanum

Naratriptanum

NCGC00181786-01

N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide

N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide

N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide

N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide

N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide

S1488_Selleck

UNII-QX3KXL1ZA2

Adrenergic Agents

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic alpha-2 Receptor Agonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2

Antihypertensive Agents

Phase 4

Serotonin

Phase 4,Phase 3,Phase 2

50-67-9

5202

Synonyms:

3-(2-Aminoethyl)-1H-indol-5-ol

3-(2-Aminoethyl)indol-5-ol

3-(b-Aminoethyl)-5-hydroxyindole

5-HT

5-HTA

5-Hydroxy-3-(b-aminoethyl)indole

5-Hydroxyltryptamine

5-Hydroxytriptamine

5-Hydroxytryptamine

5-Hydroxy-tryptamine

Antemovis

DS substance

Enteramin

Enteramine

Serotonin Agents

Phase 4,Phase 3,Phase 2

Vasoconstrictor Agents

Phase 4,Phase 1,Phase 2

Serotonin 5-HT1 Receptor Agonists

Phase 4

Dopamine

Approved

Phase 3

51-61-6, 62-31-7

681

Synonyms:

(3H)-Dopamine

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-dihydroxyphenyl)ethylamine

2-(3,4-Dihydroxyphenyl)ethylamine

2-benzenediol

3,4-dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-Aminoethyl)catechol

4-(2-aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)-Pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

a-(3,4-Dihydroxyphenyl)-b-aminoethane

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

ASL 279

BIDD:ER0506

Biomol-NT_000001

BPBio1_001123

BSPBio_001932

C03758

CHEBI:18243

CHEMBL59

CID681

cMAP_000036

cMAP_000065

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

dopamine

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine [INN:BAN]

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydroxytyramin

hydroxytyramine

Hydroxytyramine

IDI1_000780

intropin

Intropin

Intropin [*hydrochloride*]

IP 498

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L000232

L-DOPAMINE

LDP

Lopac0_000586

Lopac-H-8502

LS-159

Medopa (TN)

m-Hydroxytyramine hydrochloride

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

Spectrum_001012

SPECTRUM1505155

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

ST048774

STK301601

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

Risperidone

Approved, Investigational

Phase 3

106266-06-2

5073

Synonyms:

106266-06-2

3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one

3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[

3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,

3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,

3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

AB00514010

AC-1306

AC1L1JJU

Belivon

BIDD:GT0262

Bio-0092

BRD-K53857191-001-04-5

BRN 4891881

Buspirone

C23H27FN4O2

CAS-106266-06-2

CHEBI:8871

CHEMBL85

CID5073

Consta, Risperdal

CPD000466323

D00426

D018967

DB00734

EU-0101074

HMS1571M19

HMS2051H07

HMS2089C22

HSDB 7580

I01-1156

Jsp000573

KS-1106

L000510

Lopac-R-118

LS-134196

MLS000759429

MLS001165758

MLS001424081

MolPort-002-885-858

NCGC00015883-01

NCGC00015883-02

NCGC00015883-03

NCGC00094352-01

NCGC00094352-02

NCGC00094352-03

NCGC00179257-01

Prestwick0_001029

Prestwick1_001029

R 62 766

R 64 766, Risperdal, Risperidone

R 64,766

R 64766

R-118

R64,766

R-64,766

R64766

R-64766

R-64-766

Rispen

Risperdal

Risperdal (TN)

Risperdal Consta

Risperdal M-Tab

risperdone

Risperidal

Risperidal M-Tab

Risperidona

Risperidona [Spanish]

risperidone

Risperidone

Risperidone (JAN/USAN/INN)

Risperidone (RIS)

Risperidone [USAN:BAN:INN]

Risperidone, placebo

Risperidonum

Risperidonum [Latin]

Risperin

Rispolept

Rispolin

S1615_Selleck

SAM001246595

Sequinan

SMR000466323

SPBio_003078

Spiron

STK646402

TL8000230

UNII-L6UH7ZF8HC

Serotonin Antagonists

Phase 3

Tranquilizing Agents

Phase 3

Dopamine Agents

Phase 3

Dopamine Antagonists

Phase 3

Psychotropic Drugs

Phase 3,Phase 2

Antipsychotic Agents

Phase 3

Central Nervous System Depressants

Phase 3

Fluoxetine

Approved, Vet_approved

Phase 2

54910-89-3

3386

Synonyms:

(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine

(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine

(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine

(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

(+/-)-Fluoxetine

(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine

(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine

(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine

(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]

(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine

3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

52341-67-0

54910-89-3

57226-07-0

59333-67-4 (hydrochloride)

AB00053774

AC-14564

AC1L1FTH

Adofen

AKOS003663021

Animex-On

Bio-0787

Biomol-NT_000152

BPBio1_000354

BPBio1_000509

BRD-A31159102-001-01-9

BRD-A31159102-003-05-6

BSPBio_000461

BSPBio_003375

C17H18F3NO

CHEBI:5118

CHEMBL41

CID3386

D00326

DB00472

Deprex

DivK1c_006819

dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

Eufor

Floxetine

Fluctin

Fluoxeren

Fluoxetin

Fluoxetina

Fluoxetina [INN-Spanish]

Fluoxetina [Spanish]

fluoxetine

Fluoxétine

fluoxetine (Prozac)

Fluoxetine (TN)

Fluoxetine (USAN/INN)

Fluoxetine [USAN:INN:BAN]

Fluoxetine Hcl

Fluoxetine Hydrochloride

Fluoxetinum

Fluoxetinum [INN-Latin]

Fluval

Fontex

Foxetin

HMS2090H14

KBio1_001763

KBio2_002159

KBio2_004727

KBio2_007295

KBio3_002595

KBioGR_001166

KBioSS_002159

L000931

Lilly-110140

Lopac0_000558

LS-31040

Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine

Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine

MolPort-001-683-482

NCGC00015428-10

NCGC00024879-03

NCGC00024879-04

nchembio.534-comp2

N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine

N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine

N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine

N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

NSC283480

Portal

Prestwick0_000511

Prestwick1_000511

Prestwick2_000511

Prestwick3_000511

Prozac

Prozac Weekly

Pulvules

Reconcile

Reneuron

Sarafem

SPBio_001815

SPBio_002382

SpecPlus_000723

Spectrum_001679

Spectrum2_001658

Spectrum3_001648

Spectrum4_000613

Spectrum5_001518

STK734483

TL8003595

UNII-01K63SUP8D

SRX246

Phase 1, Phase 2

Serotonin Uptake Inhibitors

Phase 2

Natriuretic Agents

Phase 1, Phase 2

Coagulants

Phase 1, Phase 2

Neurotransmitter Uptake Inhibitors

Phase 2

Cytochrome P-450 CYP2D6 Inhibitors

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Hemostatics

Phase 1, Phase 2

Hormones

Phase 1, Phase 2

Vasopressins

Phase 1, Phase 2

Antidepressive Agents

Phase 2

Antidepressive Agents, Second-Generation

Phase 2

Arginine Vasopressin

Phase 1, Phase 2

Interventional clinical trials:

id	Name	Status	NCT ID	Phase
1	Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder	Unknown status	NCT02048241	Phase 4
2	Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order	Terminated	NCT00282165	Phase 4
3	Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.	Completed	NCT00399698	Phase 3
4	Psychotherapy for Intermittent Explosive Disorder	Completed	NCT00667212	Phase 2
5	Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder	Completed	NCT02055638	Phase 1, Phase 2
6	A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder	Completed	NCT00078754	Phase 2
7	A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED	Completed	NCT00127400	Phase 2

Search NIH Clinical Center for Intermittent Explosive Disorder

Sources

Genetic Tests for Intermittent Explosive Disorder

Sources

Anatomical Context for Intermittent Explosive Disorder

MalaCards organs/tissues related to Intermittent Explosive Disorder:

³⁹

Amygdala, Brain

Sources

Publications for Intermittent Explosive Disorder

Articles related to Intermittent Explosive Disorder:

(show top 50) (show all 82)

id	Title	Authors	Year
1	Amygdala hyperactivation to angry faces in intermittent explosive disorder. ( 27145325 )	McCloskey M.S....Coccaro E.F.	2016
2	Social cognition in Intermittent Explosive Disorder and aggression. ( 27621104 )	Coccaro E.F....Lee R.J.	2016
3	Negative urgency and reward/punishment sensitivity in intermittent explosive disorder. ( 27155024 )	Puhalla A.A....McCloskey M.S.	2016
4	Prevalence of DSM-IV Intermittent Explosive Disorder in Black Adolescents: Findings From the National Survey of American Life, Adolescent Supplement. ( 27078052 )	Oliver D.G....Jackson J.S.	2016
5	Comorbid intermittent explosive disorder and posttraumatic stress disorder: Clinical correlates and relationship to suicidal behavior. ( 27624432 )	Fanning J.R....Coccaro E.F.	2016
6	The cross-national epidemiology of DSM-IV intermittent explosive disorder. ( 27572872 )	Scott K.M....Kessler R.C.	2016
7	Development of a screening questionnaire for DSM-5 intermittent explosive disorder (IED-SQ). ( 28088746 )	Coccaro E.F....McCloskey M.S.	2016
8	Differential fMRI BOLD responses in amygdala in intermittent explosive disorder as a function of past Alcohol Use Disorder. ( 27693977 )	Coccaro E.F....Phan K.L.	2016
9	Substance use disorders: Relationship with intermittent explosive disorder and with aggression, anger, and impulsivity. ( 27442963 )	Coccaro E.F....Lee R.	2016
10	Defense styles in Intermittent Explosive Disorder. ( 27086223 )	Puhalla A.A....Coccaro E.F.	2016
11	Single Case Study: Neuropsychological Functioning in a Patient Diagnosed with Intermittent Explosive Disorder Pre and Post Neurosurgery. ( 27161981 )	Alvarez-Alonso M.J....Jurado-Barba R.	2016
12	White Matter Integrity Reductions in Intermittent Explosive Disorder. ( 27206265 )	Lee R....Coccaro E.F.	2016
13	Verbal versus physical aggression in Intermittent Explosive Disorder. ( 25534757 )	Look A.E....Coccaro E.F.	2015
14	The experience of aggressive outbursts in Intermittent Explosive Disorder. ( 25541537 )	Kulper D.A....Coccaro E.F.	2015
15	The coherence and correlates of intermittent explosive disorder amongst West Papuan refugees displaced to Papua New Guinea. ( 25754605 )	Tay A.K....Silove D.	2015
16	Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study. ( 26105140 )	Cremers H....Coccaro E.	2015
17	Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. ( 26277033 )	Coccaro E.F....Irwin M.R.	2015
18	Emotional intelligence and impulsive aggression in Intermittent Explosive Disorder. ( 25477263 )	Coccaro E.F....Lee R.	2015
19	Emotion regulation deficits in intermittent explosive disorder. ( 27539871 )	Fettich K.C....Coccaro E.F.	2015
20	Intermittent Explosive Disorder and aversive parental care. ( 25064384 )	Lee R....Coccaro E.F.	2014
21	Emotion regulation deficits in intermittent explosive disorder. ( 25403171 )	Fettich K.C....Coccaro E.F.	2014
22	Relationship between psychopathy, aggression, anger, impulsivity, and intermittent explosive disorder. ( 24760575 )	Coccaro E.F....McCloskey M.S.	2014
23	Doing Psychiatry Right: A Case of Severe Avoidant Personality Disorder with Obsessive-compulsive Personality Disorder, Obsessive Compulsive Disorder, Intermittent Explosive Disorder and Sexual Paraphilias. ( 25035563 )	Hebbar S.	2014
24	Validity of the new A1 and A2 criteria for DSM-5 intermittent explosive disorder. ( 24321204 )	Coccaro E.F....McCloskey M.S.	2014
25	Intermittent explosive disorder: a study in personalized psychopharmacotherapy. ( 24441311 )	Leahy L.G.	2014
26	Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. ( 25300440 )	Jenkins A.L....Coccaro E.F.	2014
27	History of childhood maltreatment in intermittent explosive disorder and suicidal behavior. ( 24935900 )	Fanning J.R....Coccaro E.F.	2014
28	Elevated Plasma Oxidative Stress Markers in Individuals with Intermittent Explosive Disorder and Correlation with Aggression in Humans. ( 24582164 )	Coccaro E.F....Gozal D.	2014
29	Common and distinct neural correlates of inhibitory dysregulation: stroop fMRI study of cocaine addiction and intermittent explosive disorder. ( 25106072 )	Moeller S.J....Alia-Klein N.	2014
30	Intermittent explosive disorder: associations with PTSD and other Axis I disorders in a US military veteran sample. ( 24907536 )	Reardon A.F....Miller M.W.	2014
31	Intermittent explosive disorder amongst women in conflict affected Timor-Leste: associations with human rights trauma, ongoing violence, poverty, and injustice. ( 23950885 )	Rees S....Steel Z.	2013
32	Achieving convergence between a community-based measure of explosive anger and a clinical interview for intermittent explosive disorder in Timor-Leste. ( 23835102 )	Liddell B.J....Steel Z.	2013
33	Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. ( 24352431 )	Coccaro E.F....Coussons-Read M.	2013
34	Intermittent explosive disorder and DSM-5: a flawed conceptualization of pathological anger. ( 23719736 )	Anand S.	2013
35	The prevalence and correlates of intermittent explosive disorder in Iraq. ( 22443168 )	Al-Hamzawi A....McLaughlin K.A.	2012
36	Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. ( 22535310 )	Coccaro E.F.	2012
37	Striatal activity in borderline personality disorder with comorbid intermittent explosive disorder: sex differences. ( 22464337 )	Perez-Rodriguez M.M....New A.S.	2012
38	Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. ( 22752056 )	McLaughlin K.A....Kessler R.C.	2012
39	The relationship between childhood exposure to trauma and intermittent explosive disorder. ( 22464047 )	Nickerson A....Hofmann S.G.	2012
40	Genomic architecture of aggression: rare copy number variants in intermittent explosive disorder. ( 21812102 )	Vu T.H....Girirajan S.	2011
41	Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. ( 20709410 )	Yoshimasu K....Kawakami N.	2011
42	Intermittent explosive disorder: development of integrated research criteria for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. ( 21295216 )	Coccaro E.F.	2011
43	Treating intermittent explosive disorder. Emerging data show medication and cognitive behavioral therapy may help some patients. ( 21786470 )		2011
44	Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. ( 19767013 )	Coccaro E.F....Kavoussi R.J.	2010
45	Expert witness claimed that a defendant had "intermittent explosive disorder," GMC hears. ( 21147742 )	Dyer C.	2010
46	A family history study of intermittent explosive disorder. ( 20488459 )	Coccaro E.F.	2010
47	Latent structure of intermittent explosive disorder in an epidemiological sample. ( 20064645 )	Ahmed A.O....Berman M.E.	2010
48	Deep brain stimulation of the orbitofrontal projections for the treatment of intermittent explosive disorder. ( 20672913 )	Maley J.H....Richardson D.	2010
49	Proactive, reactive, and romantic relational aggression in adulthood: measurement, predictive validity, gender differences, and association with Intermittent Explosive Disorder. ( 19822329 )	Murray-Close D....Coccaro E.F.	2010
50	Unhealthy aggression: intermittent explosive disorder and adverse physical health outcomes. ( 20496987 )	McCloskey M.S....Coccaro E.F.	2010

Sources

Genes for Intermittent Explosive Disorder

Genes related to Intermittent Explosive Disorder (0 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication
1	SLC6A4	Solute Carrier Family 6 Member 4	33.02	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
2	CGA	Glycoprotein Hormones, Alpha Polypeptide	25.71	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
3	RUVBL1	RuvB Like AAA ATPase 1	24.43	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
4	CTSH	Cathepsin H	23.84	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
5	CHRFAM7A	CHRNA7 (Exons 5-10) And FAM7A (Exons A-E) Fusion	23.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
6	CHRNA7	Cholinergic Receptor Nicotinic Alpha 7 Subunit	23.72	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
7	ADRB1	Adrenoceptor Beta 1	23.31	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
8	SMUG1	Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1	22.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
9	HTR1A	5-Hydroxytryptamine Receptor 1A	22.72	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
10	CRP	C-Reactive Protein	22.31	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
11	IL6	Interleukin 6	22.27	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
12	HTR7	5-Hydroxytryptamine Receptor 7	22.21	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
13	NPY	Neuropeptide Y	22.19	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
14	SMOC1	SPARC Related Modular Calcium Binding 1	18.67	GeneCards inferred via : Disorders (show sections)
15	GABRA2	Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit	14.36	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
16	PRL	Prolactin	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : DISEASES inferred (show sections)
17	GOLPH3	Golgi Phosphoprotein 3	12.79	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
18	MFAP4	Microfibril Associated Protein 4	8.67	GeneCards inferred via : Disorders (show sections)

Sources

Variations for Intermittent Explosive Disorder

Sources

Expression for Intermittent Explosive Disorder

Search GEO for disease gene expression data for Intermittent Explosive Disorder.

Sources

Pathways for Intermittent Explosive Disorder

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

id	Super pathways	Score	Top Affiliating Genes
1	Peptide ligand-binding receptors ⁶² Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶² Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶² Formyl peptide receptors bind formyl peptides and many other ligands ⁶² G alpha (i) signalling events ⁶² GPCR ligand binding ⁶² GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁷ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶² Peptide GPCRs ¹ Relaxin receptors ⁶² Tachykinin receptors bind tachykinins ⁶² Vasopressin-like receptors ⁶²	13.19	ADRB1 CGA CHRNA7 GABRA2 HTR1A HTR7
2	Monoamine GPCRs ¹ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶² Adrenoceptors ⁶² Amine ligand-binding receptors ⁶² Dopamine receptors ⁶² Histamine receptors ⁶² Muscarinic acetylcholine receptors ⁶² Serotonin receptors ⁶²	11.64	ADRB1 HTR1A HTR7
3	Serotonergic synapse ³⁷	11.6	HTR1A HTR7 SLC6A4
4	Glucocorticoid receptor regulatory network ¹	11.35	CGA IL6 PRL
5	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.23	CHRFAM7A CHRNA7 HTR1A IL6 SLC6A4
6	Regulation of lipolysis in adipocytes ³⁷	11.06	ADRB1 CGA NPY
7	Overview of nanoparticle effects ¹	10.71	CRP IL6
8	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁵⁸	10.58	HTR1A HTR7 SLC6A4

Sources

GO Terms for Intermittent Explosive Disorder

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.76	CRP CTSH IL6 SLC6A4
2	circadian rhythm	GO:0007623	9.58	HTR7 PRL SLC6A4
3	positive regulation of JAK-STAT cascade	GO:0046427	9.43	IL6 PRL
4	positive regulation of cell proliferation	GO:0008284	9.43	CGA CHRNA7 CTSH HTR1A IL6 PRL
5	behavior	GO:0007610	9.37	HTR1A NPY
6	negative regulation of organ growth	GO:0046621	9.32	CGA SLC6A4
7	negative regulation of lipid storage	GO:0010888	9.26	CRP IL6
8	adenylate cyclase-inhibiting serotonin receptor signaling pathway	GO:0007198	9.16	HTR1A HTR7
9	vasoconstriction	GO:0042310	8.8	HTR1A HTR7 SLC6A4

Molecular functions related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	9.33	CGA NPY PRL
2	serotonin binding	GO:0051378	8.96	HTR1A HTR7
3	extracellular ligand-gated ion channel activity	GO:0005230	8.8	CHRFAM7A CHRNA7 GABRA2

Sources

Sources for Intermittent Explosive Disorder

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ GeneTests

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MeSH

⁴³ MESH via Orphanet

⁴⁴ MGI

⁴⁵ NCBI Bookshelf

⁴⁶ NCI

⁴⁷ NCIt

⁴⁸ NDF-RT

⁴⁹ NIH Clinical Center

⁵⁰ NIH Rare Diseases

⁵¹ NINDS

⁵² Novoseek

⁵³ Novus Biologicals

⁵⁴ OMIM

⁵⁵ OMIM via Orphanet

⁵⁶ Orphanet

⁵⁷ PathCards

⁵⁸ PharmGKB

⁵⁹ PubMed

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via Orphanet

⁶⁶ UniProtKB/Swiss-Prot

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ Wikipedia

Intermittent Explosive Disorder malady

Aliases & Classifications for Intermittent Explosive Disorder

Aliases & Descriptions for Intermittent Explosive Disorder:

Classifications:

External Ids:

Summaries for Intermittent Explosive Disorder

Related Diseases for Intermittent Explosive Disorder

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Intermittent Explosive Disorder via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:

Symptoms & Phenotypes for Intermittent Explosive Disorder

MGI Mouse Phenotypes related to Intermittent Explosive Disorder:

Drugs & Therapeutics for Intermittent Explosive Disorder

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Intermittent Explosive Disorder

Anatomical Context for Intermittent Explosive Disorder

MalaCards organs/tissues related to Intermittent Explosive Disorder:

Publications for Intermittent Explosive Disorder

Articles related to Intermittent Explosive Disorder:

Genes for Intermittent Explosive Disorder

Genes related to Intermittent Explosive Disorder (0 elite genes):

Variations for Intermittent Explosive Disorder

Expression for Intermittent Explosive Disorder

Pathways for Intermittent Explosive Disorder

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

GO Terms for Intermittent Explosive Disorder

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

Molecular functions related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

Sources for Intermittent Explosive Disorder